| VIKING THERAPEUTICS |
| USA |
| Gesundheit |
| US92686J1060 / A12GD6 |
| 1VT (Frankfurt) / VKTX (NASDAQ) |
| FRA:1VT, ETR:1VT, 1VT:GR, NASDAQ:VKTX |
| - |
| https://www.vikingtherape.. |
|
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for metabolic and endocrine disorders. The company's lead program, VK2735, is a dual GLP-1/GIP receptor agonist currently in Phase 3 clinical..
>Volltext.. |
| 3091.11 Mio. EUR |
| 2568.62 Mio. EUR |
| - |
| -432.31 Mio. EUR |
| -407.09 Mio. EUR |
| -3.57 EUR |
| - |
| 101.8 Mio. EUR |
| - |
| 5.67 |
| - |
| -244.89% |
| - |
| - |
| - |
| - |
| VIKING THERAPEUTICS, VIKING THERAPEUTIC |
| 24.05.26 |
|
||||
|